EVALUATION OF THE CLINICAL AND ECONOMIC EFFICIENCY OF PHARMACOTHERAPY OF DIABETIC POLYNEUROPATHY


Citar

Texto integral

Resumo

According to randomized clinical trials ALADIN III (1999), SIDNEY (2003) and study performed by D. Ziegler et al. (2009), "cost-effectiveness" ratio in the treatment of diabetic polyneuropathy with thioctic acid and Actovegin showed an economic advantage of thioctic acid in the short-term use (21 days), while Actovegin has demonstrated clinical and economic benefit in long-term therapy (5-6 months).

Sobre autores

Nikolay Matveev

N Matveev

Bibliografia

  1. Ametov A, Barinov A, O, Brien P. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha - lipolic acid: the SYDNEY trial. Diabetes Care 2003;26:770-76.
  2. Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991;41:1315-17.
  3. Boulton AJM, Gries FA, Jervell JA: Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15:508-14.
  4. Comi G. et al. and the Italian Diabetic Nephropathy Committee. The Italian multicenter study on the prevalence of distal symmetric polyneuropathy: correlation between clinical variables and nerve conduction parameters. Electroencephalogr Clin Neurophysiol 1999;50:546-52.
  5. Dyck P. et al. Prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in population-based cohort: Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24.
  6. Dyck PJ, Dyck PJB. Diabetic polyneuropathy: section III. In Diabetic Neuropathy. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelphia, W.B. Saunders 1999:255-78.
  7. Dyck PJ. Severity and Staging of Diabetic Polyn-europathy in Textbook of Diabetic. Neuropathy 2003:171-77.
  8. Dyck PJ: Severity and staging of diabetic polyneuropathy. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme 2003:170-75.
  9. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 1997;20(5):836-43.
  10. Franklin GM, Kahn LB, Baxter J, et al. Sensory neuropathy in noninsulin-dependent diabetes mellitus. Am J Epidemiol 1990;131:633-43.
  11. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am. J Med 1999;107:2-8.
  12. Jansen W, Beck E. Treatment of the diabetic polyneuropathy - a controlled double blind study. Die Medizinische Welt 1987;38:838-41.
  13. King H, Aubert R, Herman W. Global burden of diabetes 1995-2025. Diabetes Care 1998;21:1414-31.
  14. MacDonald BK et al. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000;123:665-76.
  15. Manes Ch, Papazoglou N, et al. Prevalence of Diabetic Neuropathy and Foot Ulceration: Identification of Potential Risk Factors-A Population-Based Study. Wounds 2002;14(1):11-15.
  16. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy: report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38:1456-61.
  17. Melton LJ III, Dyck PJ. Epidemiology. In Diabetic Neuropathy. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelphia, W.B. Saunders 1999:239-78.
  18. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes. New Engl J Med 1995;333:39-84.
  19. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88.
  20. Reljanovic M, Reichel G, Rett K, еt al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999;31:171-79.
  21. Savettieri G, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Neurology 1993;43:1115-20.
  22. Tesfaye S, Chaturvedi N, Simon EM, et al. Vascular Risk Factors and Diabetic Neuropathy. N Eng J Med 2005;4(352):341-50.
  23. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38(6):869-80.
  24. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.
  25. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122(8):561-68.
  26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of Diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;70:1009-18.
  27. Thomas PK: Classification of the diabetic neuropathies. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. Stuttgart, Thieme 2003:175-77.
  28. Thomas PK: Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997;46(2):54-57.
  29. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21(3):35-8.
  30. Walters DA, Gatling W, Mullee MA, et al. The distribution and severity of diabetic foot disease: A community-based study with comparison to a nondiabetic group. Diabetic Med 1992;9:354-58.
  31. Watkins PJ, Thomas PK. Diabetes mellitus and the nervous system. J Neurol Neurosurg Psychiatry 1998;65(5):620-32.
  32. Young MJ, Boulton AJM, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150-54.
  33. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized conrolled trial (ALADIN study). Diabetologia 1995;38:1425-33.
  34. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic A in Diabetic neuropathy. Diabetes Care 1999;22(8):1296-301.
  35. Ziegler D, Movsesyan L, Mankovsky B, et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009;32(8):1479-84.
  36. Ziegler D, Nowak H, Kempler P. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004;21(2):114-21.
  37. Ziegler D, Schatz H, Conrad F, et al. Effects of threatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diab Care 1997;20:369-73.
  38. Zyegler D, Reljanovic M, Mehnert H, et all. Alfa-Lipoic acid in the treatment of diabetic polyneuropathy in Germany current evidence front clinical trails. Exp Clin Endocrinol Diabetes 1999;107:421-30.
  39. Аметов А.С., Моргоева Ф.Э., Строков И.А. Диабетическая энцефалопатия и полиневропатия: терапевтические возможности актовегина // РМЖ 2005. № 6.
  40. Аметов А.С., Солуянова Т.Н. Место Актовегина в лечении и профилактике сахарного диабета типа 2 // Международный эндокринологический журнал 2007. № 4 (10).
  41. Аметов А.С., Солуянова Т.Н. Эффективность актовегина в лечении диабетической полинейропатии // Медицинский совет 2010. № 1-2.
  42. Аметов А.С., Строков И.А., Баринов А.Н. и др. Альфа-липоевая кислота в лечении симптомной диабетической полиневропатии: symptomatic diabetic neuropathy (SYDNEY) trial // Фарматека 2004. № 11 (88). С. 69-73.
  43. Балаболкин М.И. Эндокринология. М., 1998. 687 с.
  44. Борисенко О.В., Воробьев П.А. и др. Проблемы стандартизации в здравоохранении. 2008.
  45. Демидова И.Ю., Храмилин В.Н., Игнатова О.Ю. Диабетическая дистальная полинейропатия // Эндокринная хирургия. 2008. № 1. С. 29.
  46. Гурьева И.В., Комелягина Е.Ю., Кузина И.В. Диабетическая периферическая сенсомоторная нейропатия. Патогенез, клиника и диагностика. Методические рекомендации. М., 2000. 23 с.
  47. Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М., 2000. 227 с.
  48. Оруджева С.А., Звягин А.А. Оценка функциональных резервов сердечно-сосудистой системы у больных сахарным диабетом. Опасности анестезии и возможности анестезиологического обеспечения больных с гнойно-некротическими формами синдрома диабетической стопы // Новости анестезиологии и реаниматологии 2006. № 3. С. 1-18.
  49. Применение Актовегина у больных сахарным диабетом: Методические рекомендации / Под ред. акад. РАМН В.Г. Кукес. М., 2006. 30 с.
  50. Прихожан В.М. Классификация диабетической нейропатии // Пробл. эндокринол 1987. Т. 33. № 3. С. 79-85.
  51. Скворцов В.В. К вопросу о диагностике и лечении диабетической полинейропатии. www.diabet.ru/articles/Sent/Neuro.pdf
  52. Строков И.А., Баринов А.Н., Новосадова М.В. и др. Клинические методы оценки тяжести диабетической полиневропатии // Неврологический журнал 2000. № 5. С. 14-19.
  53. Храмилин В.Н, Демидова И.Ю. Диабетическая нейропатия. Методические рекомендации. М., 2003. 30 с.
  54. Яворская В.А., Гребенюк А.В. Клинический опыт применения Актовегина в неврологии. 2000.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2011

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies